CBRE Group, Inc. has been hired to sell Eli Lilly’s biomanufacturing plant in Vacaville, CA. The multi-purpose facility is among the largest bulk API manufacturing facilities for recombinant microbial-based biopharmaceuticals in the U.S.

The site includes a 52-acre campus, with 28 acres available for future expansion. The 78,198-sq.-ft. facility includes a downstream processing building, capable of handling complex purification steps, analytical labs for raw materials, environmental monitoring and release testing, and a mechanical workshop for equipment maintenance and calibration.

CBRE Brokerage Services Life Sciences group will direct the marketing to U.S. and international biopharma firms.